<DOC>
	<DOCNO>NCT00841139</DOCNO>
	<brief_summary>Conventional measure use treatment chronic heart failure act predominantly reduce work perform heart . In recent study , investigator show one drug ( perhexiline ) substantially improve symptom cardiac function heart failure . The investigator wish confirm finding test whether drug act alter heart 's energy source thus augment energetic status work efficiency heart .</brief_summary>
	<brief_title>Metabolic Manipulation Chronic Heart Failure</brief_title>
	<detailed_description>Perhexiline maleate antianginal agent increase efficiency energy production shift substrate utilisation free fatty acid towards glucose . We show perhexiline therapy highly effective improve exercise capacity , symptom cardiac function patient systolic heart failure ischaemic non ischaemic aetiology . Perhexiline act inhibit carnitine palmitoyl transferase-1 ( CPT-1 ) CPT-2 , key enzyme mitochondrial free fatty acid uptake . This lead increase myocardial glucose substrate utilization . Further wish ascertain whether drug improve cardiac energetics efficiency alter substrate utilization . In proposal assess cardiac function ( cardiac Magnetic Resonance Imaging MRI ) , cardiac energetic status ( cardiac Magnetic Resonance Spectroscopy MRS ) , cardiac efficiency ( via pressure-volume loop ) substrate utilization ( via leave right heart catheterization ) , follow one month perhexiline therapy placebo patient symptomatic idiopathic dilate cardiomyopathy optimal conventional heart failure medication . An interim analysis plan 20 patient .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Perhexiline</mesh_term>
	<criteria>Optimallymedicated idiopathic dilate cardiomyopathy Symptomatic ( NYHA IIbIII ) Impaired leave ventricular systolic function ( EF &lt; 40 % ) Abnormal liver function test ( define twice upper limit normal ( ULN ) ) Concomitant use Amiodarone , Quinidine , Haloperidol Selective serotonin ( 5HT ) uptake inhibitor Fluoxetine Paroxetine may inhibit CYP2D6 enzyme . Preexisting evidence peripheral neuropathy . Women childbearing potential . Patients implantable cardiac device ( contraindication MRI ) . Obesity ( BMI &gt; 32 ) Obstructive sleep apnea syndrome Patients know hypersensitivity perhexiline Patients impaired renal function ( Creatinine &gt; 250 Âµmol/L ) Valvular heart disease define moderate valvular stenosis regurgitation . Atrial Fibrillation</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>perhexiline</keyword>
	<keyword>idiopathic dilate cardiomyopathy</keyword>
	<keyword>magnetic resonance spectroscopy</keyword>
	<keyword>cardiac energetics</keyword>
</DOC>